You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Colorcon
Dow
Medtronic
Merck

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,759,401

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,759,401 protect, and when does it expire?

Patent 8,759,401 protects AKTEN and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 8,759,401
Title:Aqueous gel formulation and method for inducing topical anesthesia
Abstract: Disclosed is a stable aqueous gel formulation suitable for topical use comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile and has low particulate count. Also disclosed is a method of inducing topical anesthesia on a tissue or organ, e.g., the eye, of an animal comprising providing a stable aqueous gel formulation comprising water, an anesthetic, a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile, and topically administering an effective amount of the aqueous gel formulation to the tissue or organ of the animal.
Inventor(s): Alam; Abu (Lake Forest, IL), Reichel; Elias (Weston, MA), Busbee; Brandon (Nashville, TN)
Assignee: Akorn, Inc. (Lake Forest, IL)
Application Number:13/961,453
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use;

Drugs Protected by US Patent 8,759,401

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Akorn AKTEN lidocaine hydrochloride GEL;OPHTHALMIC 022221-001 Oct 7, 2008 RX Yes Yes   Start Trial   Start Trial Y METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Merck
Baxter
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.